Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study

• Published in: Journal of hepatology Vol. 68; no. 3; pp. 476 - 484
• Main Authors: Kim, Gyuri, Jang, Suk-Yong, Nam, Chung Mo, Kang, Eun Seok
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2018
• Subjects: Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - epidemiology; Carcinoma, Hepatocellular - pathology; Case-Control Studies; Cohort study; Diabetes; Diabetes Mellitus - epidemiology; Female; Hepatocellular carcinoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - drug therapy; Hypercholesterolemia - epidemiology; Liver cirrhosis; Liver Cirrhosis - epidemiology; Liver Neoplasms - diagnosis; Liver Neoplasms - epidemiology; Liver Neoplasms - pathology; Longitudinal Studies; Male; Middle Aged; Protective Factors; Republic of Korea - epidemiology; Risk Factors; Statin; Republic of Korea; Hepatocellular carcinoma; Statin; Diabetes; Liver cirrhosis; Cohort study
• ISSN: 0168-8278; 1600-0641
• DOI: 10.1016/j.jhep.2017.10.018

[Display omitted] •Statin use was significantly associated with a reduced risk of HCC compared with nonusers.•The beneficial effect of statins was shown in patients with diabetes mellitus and relatively good glycemic control.•Statin significantly reduced the risk of HCC in subjects with cirrhosis or diabetes mellitus, a high risk factor for HCC. Statins are widely used to treat hypercholesterolemia. Statins may prevent hepatocellular carcinoma (HCC), but have not yet been fully studied, particularly in patients at high risk. Therefore, we investigated the risk of HCC after statin use in the whole general population and evaluated the effects of preexisting diabetes mellitus (DM) and liver cirrhosis (LC) on that risk. A nationwide, nested case-control study was conducted with data from the National Health Insurance Service Physical Health Examination Cohort 2002–2013 in the Republic of Korea. Individuals diagnosed with HCC were matched to controls based on the time of the follow-up, sex, and age at index date. Odds ratios (ORs) and 95% confidence intervals (CIs) for HCC associated with statin use were analyzed by multivariable conditional logistic regression analyses. In total, 1,642 HCC cases were matched to 8,210 control individuals from 514,866 participants. Statin use was associated with reduced risk of HCC development (adjusted OR [AOR] 0.44; 95% CI 0.33–0.58) compared with nonusers. The reduction in risk was significant in the presence (AOR 0.28; 95% CI 0.17–0.46) and absence of DM (AOR 0.53; 95% CI 0.39–0.73) and in the presence (AOR 0.39; 95% CI 0.26–0.60) and absence of LC (AOR 0.42; 95% CI 0.32–0.57). Statin use also significantly reduced the risk of HCC among patients with DM, without chronic complications (AOR 0.19; 95% CI 0.08–0.46) or with chronic complications (AOR 0.34; 95% CI 0.19–0.64), compared to nonusers. Statin use may have a beneficial inhibitory effect on HCC development, particularly in patients with DM or LC, at high risk of HCC. In this longitudinal nationwide population-based nested case-control study, the association between statin use and the risk of HCC was investigated in Asian populations. Herein, we noted a beneficial effect of statin use on the development of HCC in the general population and individuals at high risk of HCC (i.e. those with diabetes or liver cirrhosis).